YD23 is a PROTAC degrader of SMARCA2 with demonstrated anticancer activity. It exhibits selective growth inhibition against SMARCA4-mutant lung cancer cells in vitro, supporting its investigation in oncology research focused on synthetic lethality and targeted protein degradation.